BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Angiogenesis
,
Leukemia
,
Retina
,
Alcohol
,
Lipopolysaccharide
,
rs2476601
,
GATA1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
relapsed or refractory multiple myeloma
Summary
General Info
Curated Studies
Most Correlated Studies
Multiple myeloma U266 cells with CD9 overexpression
Explore Curated Studies Results
Literature
Most Relevant Literature
No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
The Management of Relapsed and Refractory Multiple Myeloma.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Overall and complete response rates as potential surrogates for overall survival in relapsed/refract…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ